What is DaVita's revenue?

DaVita (DVA) generated $13.8B in revenue over the trailing twelve months, up 6.7% year over year.

Is DaVita profitable?

DaVita reported $781.4M in net income over the trailing twelve months, a 5.6% net margin.

What is DaVita's earnings per share?

DaVita's diluted EPS over the trailing twelve months is $10.71.

Where does DaVita's income statement data come from?

Every line is extracted from DaVita's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

DaVita DVA Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$13.84B+6.7%	$13.64B+6.5%	$13.32B+5.1%	$13.16B+5.1%	$12.97B+5.1%
General and administrative	$1.72B+11.1%	$1.67B+8.8%	$1.62B+5.9%	$1.59B+5.7%	$1.55B+3.0%
Compensation and benefits	——	——	——	——	——
Depreciation and amortization	$716.73M+0.5%	$715.35M-1.2%	$702.75M-5.7%	$712.27M-4.6%	$713.23M-5.5%
Goodwill impairment	$0—	$0—	$0-100%	$0-100%	$0-100%
Total costs & expenses	$11.75B+7.6%	$11.6B+8.2%	$11.27B+4.8%	$11.08B+4.1%	$10.92B+3.4%
Operating income	$2.09B+2.0%	$2.04B-2.2%	$2.05B+6.9%	$2.08B+10.7%	$2.05B+15.2%
Operating margin	15.1%-0.7pp	15%-1.3pp	15.4%+0.3pp	15.8%+0.8pp	15.8%+1.4pp
Interest expense	$590M+16.6%	$579.93M+23.3%	$570.4M+33.3%	$554.42M+41.6%	$506.11M+27.4%
Other income (expense), net	-$80.67M-8.0%	-$102.69M-47.1%	-$94.57M-53.6%	-$70.09M-8.8%	-$74.72M-110%
Income from equity method investments	$35.74M+42.3%	$33M+26.0%	$33.45M+57.5%	$27M+9.1%	$25.12M-9.4%
Income before income taxes	$1.4B-3.0%	$1.35B-12.0%	$1.38B-2.0%	$1.44B+2.3%	$1.44B+8.3%
Income tax expense	$305.19M+13.9%	$293.11M+4.8%	$280.87M+2.6%	$289.99M+9.5%	$267.97M+10.7%
Net income	$781.42M-9.1%	$746.8M-20.2%	$771.92M-6.7%	$836.27M-2.7%	$859.61M+5.4%
Net margin	5.6%-1.0pp	5.5%-1.8pp	5.8%-0.7pp	6.4%-0.5pp	6.6%0.0pp
Net income attributable to noncontrolling interests	——	——	——	——	——
Diluted earnings per share	$10.71+6.4%	$9.84-8.2%	$9.69+4.5%	$10.15+8.1%	$10.07+14.4%
Basic earnings per share	$10.93+5.8%	$10.05-8.7%	$9.92+4.2%	$10.39+7.6%	$10.33+14.0%
Weighted-average shares, diluted	295.9M-13.8%	308.3M-12.6%	319.7M-10.8%	331.7M-9.5%	343.3M-7.5%
Weighted-average shares, basic	289.6M-13.5%	301.6M-12.2%	312.4M-10.5%	324M-9.2%	335M-7.2%
Adjustment Income Loss From Equity Method Investments	——	——	——	——	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	——	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	——	——	——	——	——
Less: comprehensive income attributable to noncontrolling interest	——	——	——	——	——
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	——	——	——	——	——
Impact to revenue from performance obligations satisfied (or partially satisfied) in previous periods	——	——	——	——	——
Deferred taxes	$137.04M+373%	$86.57M+250%	$64.86M+186%	-$39.04M+24.7%	-$50.19M-28.5%
Depreciation, Amortization and Accretion, Net	$716.73M+0.5%	$715.35M-1.2%	$702.75M-5.7%	$712.27M-4.6%	$713.23M-5.5%
Effect of exchange rate changes on cash, cash equivalents and restricted cash	——	——	——	——	——
Goodwill Additions	$101.93M-52.0%	$71.68M-79.5%	$278.23M+73.2%	$211.92M+30.1%	$212.18M—
Translation and other	$66.53M—	$99.9M—	$38.02M—	——	——
Accounts payable	$68.92M+11.1%	$138.89M+8,075%	$153.58M+787%	$86.89M+205%	$62.06M+86.6%
Increase (Decrease) in Accounts Receivable	——	——	——	——	——
Increase Decrease In Accrued Income Taxes Payable	——	——	——	——	-$65.51M—
Accrued compensation and employee benefits	——	——	——	——	——
Increase (Decrease) in Inventories	——	——	——	——	——
Increase (decrease) in other current liabilities	——	——	——	——	——
Increase Decrease In Other Current Receivables And Other Current Assets	——	——	——	——	——
Increase (decrease) in other assets	$55.85M-0.1%	$40.25M-39.9%	$54.19M+174%	$60.68M+610%	$55.93M+1,614%
Increase (decrease) in all other liabilities	$12.87M—	$7.35M—	——	——	——
Add - Incremental shares under stock-based compensation plans (in shares)	——	——	——	——	——
Interest and Debt Expense	$590M+16.6%	$579.93M+23.3%	$570.4M+33.3%	$554.42M+41.6%	$506.11M+27.4%
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$1.21B+20.3%	-$1.38B-68.8%	-$1.53B-134%	-$955.5M+8.3%	-$1.52B-164%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$631.9M+12.0%	-$654.95M+15.1%	-$739.8M-6.9%	-$623.77M+9.0%	-$718.36M+17.5%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$2.03B-13.2%	$1.89B-6.7%	$1.89B-3.4%	$1.86B+2.9%	$2.34B+59.9%
Net Income Loss Attributable To Noncontrolling Interest	——	——	——	——	——
Net proceeds from issuance of common stock under employee stock plans	$20.74M-2.4%	$23.29M+13.9%	$22.83M+17.5%	$21.95M+38.3%	$21.25M+26.3%
Number of reportable segments	——	——	——	——	——
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	——	——	——	——	——
Net gains (losses) deferred	——	——	——	——	——
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax	——	——	——	——	——
Other comprehensive income (loss)	——	——	——	——	——
Membership and other income	$658.1M+20.4%	$635.88M+14.5%	$590.83M+6.8%	$593.72M-0.6%	$546.69M-6.0%
Other Noncash Income (Expense)	$17.98M—	$17.55M—	——	——	——
Other income, net (Note 6)	-$80.67M-8.0%	-$102.69M-47.1%	-$94.57M-53.6%	-$70.09M-8.8%	-$74.72M-110%
Patient care costs	$9.35B+6.7%	$9.24B+7.5%	$9.06B+6.4%	$8.88B+5.4%	$8.76B+5.0%
Payments for Repurchase of Common Stock	$994.58M-39.5%	$1.31B-5.6%	$1.4B+8.2%	$1.57B+77.1%	$1.65B+214%
Payments Of Distributions To Affiliates	$316.69M-10.2%	$324.27M-3.8%	$340.53M+11.0%	$380.92M+44.3%	$352.72M+16.2%
Payments of Financing Costs	——	——	——	——	——
Payment, Tax Withholding, Share-Based Payment Arrangement	$68.23M-7.3%	$35.29M-73.7%	$40.1M-73.5%	$70.82M-39.8%	$73.62M-51.0%
Payment related to business acquisition	——	——	——	——	——
Payments to Acquire Equity Method Investments	$29.34M+518%	$27.03M+419%	$3.17M-32.4%	$6.65M+86.5%	$4.75M-98.2%
Payments to Acquire Held-to-Maturity Securities	——	——	——	——	——
Payments to Acquire Other Investments	——	——	——	——	——
Payments to Acquire Property, Plant, and Equipment	$534.62M-7.5%	$575.86M+3.7%	$601.09M+10.5%	$574.05M+6.0%	$577.69M+6.7%
Payments to Noncontrolling Interests	——	——	——	——	——
Potential Increase Decrease In Fair Value Of Noncontrolling Interests Due To Change In Weighted Average EBITDA Multiple	——	——	——	——	——
Proceeds From Contributions From Affiliates	$8.96M-30.8%	$7.08M-51.2%	$7.88M-43.0%	$9.46M-38.8%	$12.94M-6.0%
Proceeds from Equity Method Investment, Distribution, Return of Capital	$337K-93.5%	$1.54M-76.9%	$1.64M-79.8%	$1.6M-83.6%	$5.16M-22.0%
Debt issued (Note 13)	$6.24B+4.6%	$5.61B-15.3%	$4.67B-29.5%	$7.54B+109%	$5.97B+89.6%
Sales and maturities of investments	——	——	——	$63.57M+417%	$25.42M-48.8%
Other investments, net of payments	$5.39M-5.2%	$6.72M+47.0%	$6.71M-39.0%	$6.39M-42.2%	$5.69M-48.6%
Proceeds from sales of operations and affiliates	$27.22M-7.7%	$34.17M+32.1%	$40.26M+70.3%	$35.48M+59.9%	$29.5M+22.0%
Purchase Of Treasury Stock From Related Party	$652.89M+1,961%	$484.63M—	$430.29M—	$200.26M—	$31.68M—
Repayments of Debt and Lease Obligation	$5.36B+1.0%	$4.79B-13.2%	$3.96B-27.6%	$6.23B+86.7%	$5.31B+96.9%
Dialysis patient service revenues	$13.18B+6.1%	$13.01B+6.1%	$12.73B+5.1%	$12.57B+5.4%	$12.42B+5.7%
Property, plant, and equipment additions	——	——	——	——	——
Segment Reporting Information Corporate Expenses	——	——	——	——	——
Stock-based compensation	$138.35M+28.1%	$139.95M+36.2%	$128.96M+22.3%	$116.52M+9.9%	$108.01M-3.2%
Average price paid (in dollars per share)	——	——	——	——	——
Number of shares purchased (in shares)	——	——	——	——	——
Treasury stock, value, acquired	——	——	——	——	——
Weighted Average Number Of Shares Issued Basic	——	——	——	——	——
EBIT	$2.09B+2.0%	$2.04B-2.2%	$2.05B+6.9%	$2.08B+10.7%	$2.05B+15.2%
EBITDA	$2.8B+1.6%	$2.76B-2.0%	$2.75B+3.4%	$2.79B+6.4%	$2.76B+9.1%
EBITDA	$2.8B+1.6%	$2.76B-2.0%	$2.75B+3.4%	$2.79B+6.4%	$2.76B+9.1%
EBITDA margin	20.3%-1.0pp	20.2%-1.7pp	20.7%-0.3pp	21.2%+0.3pp	21.3%+0.8pp
EBIT	$2.09B+2.0%	$2.04B-2.2%	$2.05B+6.9%	$2.08B+10.7%	$2.05B+15.2%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about DaVita.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is DaVita's revenue?: DaVita (DVA) generated $13.8B in revenue over the trailing twelve months, up 6.7% year over year.
Is DaVita profitable?: DaVita reported $781.4M in net income over the trailing twelve months, a 5.6% net margin.
What is DaVita's earnings per share?: DaVita's diluted EPS over the trailing twelve months is $10.71.
Where does DaVita's income statement data come from?: Every line is extracted from DaVita's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.